Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.
暂无分享，去创建一个
I. Waizenegger | T. Heffernan | N. Kraut | D. Rudolph | M. Gmachl | M. Petronczki | J. Marszalek | F. Trapani | C. Vellano | M. Marotti | J. Daniele | M. Hofmann | Hengyu Lu | D. Gerlach | U. Duenzinger | Annette A. Machado | Vitomir Vucenovic | M. H. Hofmann